Skip to main content
Caplight Logo









Renibus Therapeutics

Renibus Therapeutics

Private
Southlake, TexasHealthcare & Life Scienceshttps://www.renibus.com/

Last Round

Series B

Sep 12, 2023

Total Funding Raised

$187M

Company Overview

Renibus Therapeutics is a clinical-stage biopharmaceutical company that develops products to prevent disease progression, improve outcomes, and protect against organ damage associated with cardio, renal, and metabolic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaldrug developmentclinical-stageacute kidney injuryAKIchronic kidney diseaseCKDcardiorenal diseasebiotechclinical trialssmall molecule therapybiologic therapyoxidative stressinflammatory diseasedrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Renibus Therapeutics Comparables

Compare Renibus Therapeutics with similar companies based on industry and business-model similarity.

Renibus Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AM-Pharma
84%
Arch Biopartners Inc.
79%
Revelation Biosciences Inc.
79%

Renibus Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 12, 2023
Series BJul 17, 2023
DebtAug 1, 2022
SAFEAug 1, 2022
Series AFeb 15, 2022

Key People

Founding team and executive leadership

Jeff Keyser

President and CEO Renibus Therapeutics, Co-Chief Executive Officer, Co-Founder

Founding Team

Jamie Donadio

Chief Financial Officer

Executive Team

Renibus Therapeutics Investors

Notable investors and investment history

Renibus Therapeutics investors
InvestorRounds
Oxford FinanceDebt
Bios PartnersSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 23, 2026

    Monthly visitors grew 98% MoM, reaching 3.7K.

  • Mar 26, 2026

    Attending the 25th Annual Needham Virtual Healthcare Conference April 13-16, 2026.

Renibus Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Renibus Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Renibus Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouthlake, Texas
Employee Range31
Year Founded2015
Last FundingSep 12, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?